Amodio, N.; Gallo Cantafio, M.E.; Botta, C.; Agosti, V.; Federico, C.; Caracciolo, D.; Ronchetti, D.; Rossi, M.; Driessen, C.; Neri, A.;
et al. Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers 2019, 11, 236.
https://doi.org/10.3390/cancers11020236
AMA Style
Amodio N, Gallo Cantafio ME, Botta C, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A,
et al. Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers. 2019; 11(2):236.
https://doi.org/10.3390/cancers11020236
Chicago/Turabian Style
Amodio, Nicola, Maria Eugenia Gallo Cantafio, Cirino Botta, Valter Agosti, Cinzia Federico, Daniele Caracciolo, Domenica Ronchetti, Marco Rossi, Christoph Driessen, Antonino Neri,
and et al. 2019. "Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma" Cancers 11, no. 2: 236.
https://doi.org/10.3390/cancers11020236
APA Style
Amodio, N., Gallo Cantafio, M. E., Botta, C., Agosti, V., Federico, C., Caracciolo, D., Ronchetti, D., Rossi, M., Driessen, C., Neri, A., Tagliaferri, P., & Tassone, P.
(2019). Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers, 11(2), 236.
https://doi.org/10.3390/cancers11020236